DelveInsight’s, “Psoriasis Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including Psoriasis clinical trials and nonclinical stage products. It also covers the Psoriasis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Psoriasis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Psoriasis NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Psoriasis Pipeline treatment landscape of the report, click here @ Psoriasis Pipeline Outlook

 

Key Takeaways from the Psoriasis Pipeline Report

• DelveInsight’s Psoriasis Pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline treatment therapies.
• The leading Psoriasis Companies are working in the market include Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others
• Emerging Psoriasis Pipeline Therapies in the various stages of development include GN037, Clobetasol 17-Propionate Cream, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), KX01 0.01% (0.1 mg/g), MP1032, LAS41004, Calcipotriene Foam, Talarozole, U0267, and others
• On January 2023, GEN İlaç ve Sağlık Ürünleri A.Ş. has announced drug named GN037, Clobetasol 17-Propionate Cream by the phase 2. This Phase II study was designed as a multicenter, randomized, double-blind, placebo-controlled and 3-parallel arm, to assess clinical efficacy, safety, and tolerabilityGN-037 versus clobetasol 17-propionate and placebo in patients diagnosed with mild to moderate plaque psoriasis at least 6 months ago.
• On March 2023, Institut Pasteur has announced drug named Blood sample, Data collection, skin biopsies. This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a monocentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in psoriasis patients attending the dermatology department of hospital Cochin (APHP).
• On May 2023, Samsung Bioepis Co Ltd has announced drug named Humira (Adalimumab) and SB5 (Adalimumab Biosimilar) by the phase 4. This is a Phase IV, randomized, double-blind, parallel-group, multiple-dose, active comparator, multicenter clinical study to evaluate the pharmacokinetics, efficacy, safety, and immunogenicity of SB5 versus Humira in subjects with moderate to severe chronic plaque psoriasis.

 

Psoriasis Overview

Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors. It is a non-contagious dermatosis disease affecting almost 2% of the world population. The percentage of body affected by psoriasis can vary on an individual basis.

 

For further information, refer to the detailed Psoriasis Unmet Needs, Psoriasis Market Drivers, and Market Barriers, click here for Psoriasis Ongoing Clinical Trial Analysis

 

Psoriasis Emerging Drugs Profile

• Topical roflumilast: Arcutis Biotherapeutics
• GSK2982772: GlaxoSmithKline

 

Psoriasis Pipeline Therapeutics Assessment

There are approx. 80+ Psoriasis companies which are developing the therapies for Psoriasis. The Psoriasis companies which have their Psoriasis drug candidates in the most advanced stage, i.e. Registered include, Biocad.

 

Request a sample and discover the recent advances in Psoriasis Ongoing Clinical Trial Analysis and Medications, click here @ Psoriasis Treatment Landscape

 

Psoriasis Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Psoriasis Therapeutics Market include-

Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.

 

Dive deep into rich insights for drugs for Psoriasis Pipeline, click here @ Psoriasis Unmet Needs and Analyst Views

 

Scope of the Psoriasis Pipeline Report

• Coverage- Global
• Psoriasis Companies- Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.
• Psoriasis Therapies- GN037, Clobetasol 17-Propionate Cream, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), KX01 0.01% (0.1 mg/g), MP1032, LAS41004, Calcipotriene Foam, Talarozole, U0267, and others
• Psoriasis Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Psoriasis Merger and acquisitions, Psoriasis Licensing Activities @ Psoriasis Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Psoriasis Executive Summary
3. Psoriasis: Overview
4. Psoriasis Pipeline Therapeutics
5. Psoriasis Therapeutic Assessment
6. Psoriasis – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Psoriasis Collaboration Deals
9. Late Stage Products (Phase III)
10. CT-P43: Celltrion
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. EDP1815: Evelo Biosciences
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. AZD0284: AstraZeneca
17. Drug profiles in the detailed report…..
18. Early Stage Products (Preclinical)
19. AZD0284: AstraZeneca
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Psoriasis Key Companies
23. Psoriasis Key Products
24. Psoriasis- Unmet Needs
25. Psoriasis- Market Drivers and Barriers
26. Psoriasis- Future Perspectives and Conclusion
27. Psoriasis Analyst Views
28. Psoriasis Key Companies
29. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services